Role of biomarkers in studies of presymptomatic Alzheimer's disease
Tóm tắt
Biomarkers that have been developed largely for the study of patients with clinically diagnosed Alzheimer's disease (AD) can also be used in the study of cognitively normal individuals who may harbor underlying AD pathology.
A meeting of invited experts on AD biomarkers was held on November 11 and 12, 2004 to review currently available data and to discuss unmet needs for biomarker research in presymptomatic AD.
Neuroimaging biomarkers have been studied to some extent in subjects at risk for AD. These imaging techniques include volumetric magnetic resonance imaging and positron emission tomography using either fluorodeoxyglucose or newer ligands that bind directly to amyloid plaque. Similarly, biochemical measures from cerebrospinal fluid or other physiologic fluids are emerging as potentially useful tools. Such biomarkers may be used either as diagnostic tools or as indicators of disease severity when followed longitudinally. A clinical diagnosis of asymptomatic individuals using biomarkers and studies involving asymptomatic subjects may raise logistical and ethical concerns.
The technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.
Tài liệu tham khảo
Matthews B, 2003, Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease, Am J Geriatr Psychiatry., 11, 146, 10.1097/00019442-200303000-00005
Frank RA, 2003, Biological markers for therapeutic trials in Alzheimer's disease, Neurobiol Aging., 24, 521, 10.1016/S0197-4580(03)00002-2
Silbert LC, 2003, Changes in premorbid brain volume predict Alzheimer's disease pathology, Neurology, 61, 487, 10.1212/01.WNL.0000079053.77227.14
Braak H, 1997, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol Aging., 18, 351, 10.1016/S0197-4580(97)00056-0
Price JL, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease, Ann Neurol., 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Knopman DS, 2003, Neuropathology of cognitively normal elderly, J Neuropathol Exp Neurol., 62, 1087, 10.1093/jnen/62.11.1087
Tiraboschi P, 2004, The importance of neuritic plaques and tangles to the development and evolution of AD, Neurology, 62, 1984, 10.1212/01.WNL.0000129697.01779.0A
Ganguli M, 2000, Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project, Neurology, 54, 1109, 10.1212/WNL.54.5.1109
Hebert LE, 1995, Age-specific incidence of Alzheimer's disease in a community population, JAMA, 273, 1354, 10.1001/jama.1995.03520410048025
Kukull WA, 2002, Dementia and Alzheimer disease incidence: a prospective cohort study, Arch Neurol, 59, 1737, 10.1001/archneur.59.11.1737
Silverman JM, 1994, Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls, Neurology, 44, 1253, 10.1212/WNL.44.7.1253
Strittmatter WJ, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc Natl Acad Sci U S A, 90, 1977, 10.1073/pnas.90.5.1977
KQuaid.Investigators and Coordinators THSGP.Attitudes towards genetic testing in HD for PHAROS participants. World conference on Huntington disease.2005 Manchester UK
Cummings JL, 1995, Behavioral neurology of movement disorders, 179
Kayson E, 2004, Depression and suicidality at baseline in the Prospective Huntington At Risk Observational Study (PHAROS), Mov Disord., 19, 1128
Mueller EA, 1998, Brain volume preserved in healthy elderly through the eleventh decade, Neurology, 51, 1555, 10.1212/WNL.51.6.1555
Jack CR, 1999, Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment, Neurology, 52, 1397, 10.1212/WNL.52.7.1397
Visser PJ, 1999, Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment, J Neurol., 246, 477, 10.1007/s004150050387
Killiany RJ, 2000, Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease, Ann Neurol., 47, 430, 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I
Small GW, 1995, Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease, JAMA, 273, 942, 10.1001/jama.1995.03520360056039
Reiman EM, 1996, Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E, N Engl J Med., 334, 752, 10.1056/NEJM199603213341202
Reiman EM, 2001, Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease, Proc Natl Acad Sci U S A, 98, 3334, 10.1073/pnas.061509598
Reiman EM, 2004, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia, Proc Natl Acad Sci U S A, 101, 284, 10.1073/pnas.2635903100
Reiman EM, 2005, Correlations between apolipoprotein E {varepsilon}4 gene dose and brain-imaging measurements of regional hypometabolism, Proc Natl Acad Sci U S A, 102, 8299, 10.1073/pnas.0500579102
Klunk WE, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann Neurol., 55, 306, 10.1002/ana.20009
Prince JA, 2004, APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42, Neurology, 62, 2116, 10.1212/01.WNL.0000128088.08695.05
Mayeux R, 1999, Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease, Ann Neurol., 46, 412, 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A
Mayeux R, 2003, Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk, Neurology, 61, 1185, 10.1212/01.WNL.0000091890.32140.8F
DeMattos RB, 2002, Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease, Science, 295, 2264, 10.1126/science.1067568
Bradley KM, 2002, Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease, Br J Radiol., 75, 506, 10.1259/bjr.75.894.750506
Fox NC, 1999, Correlation between rates of brain atrophy and cognitive decline in AD, Neurology, 52, 1687, 10.1212/WNL.52.8.1687
Jack CR, 2000, Rates of hippocampal atrophy correlate with change in clinical status in aging and AD, Neurology, 55, 484, 10.1212/WNL.55.4.484
Jack CR, 1998, Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease, Neurology, 51, 993, 10.1212/WNL.51.4.993
Jack CR, 2004, Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD, Neurology, 62, 591, 10.1212/01.WNL.0000110315.26026.EF
Kaye JA, 2005, Asynchronous regional brain volume losses in presymptomatic to moderate AD, J Alzheimers Dis., 8, 51, 10.3233/JAD-2005-8106
O'Brien JT, 2001, Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia, Neurology, 56, 1386, 10.1212/WNL.56.10.1386
Resnick SM, 2003, Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain, J Neurosci, 23, 3295, 10.1523/JNEUROSCI.23-08-03295.2003
Rusinek H, 2003, Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging, Radiology, 229, 691, 10.1148/radiol.2293021299